NEULANDLAB evidence report
Evidence date: 2026-10-01. Research observations only.
What can I do with this stock?
Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.
Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.
Today: intraday
Evidence unavailable
No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
- No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.
Next week: five trading sessions
No qualifying opportunity
No candidate with a primary five-session horizon in the coherent source run.
- No candidate with a primary five-session horizon in the coherent source run.
Long term: one to three years
Research only
A financial screen alone does not establish an investment recommendation.
- A current, source-backed thesis and valuation review is required.
Investment evidence
- Statement coverage
- FULL_STATEMENTS
- Financial source retrieved
- 2026-09-23T23:41:38.244641+00:00
Metrics
- latest_annual_period
- 2026-03-31
- revenue
- 20229854000.0
- net_income
- 3639984000.0
- operating_cash_flow
- 3382452000.0
- free_cash_flow
- -588869000.0
- total_assets
- 29301377000.0
- total_liabilities
- 10556648000.0
- total_equity
- 18744729000.0
- cash
- 766704000.0
- total_debt
- 3012722000.0
- revenue_growth
- 0.41035321062637364
- earnings_growth
- 0.399412013697382
- net_margin
- 0.17993130350817163
- roe
- 0.1941870698690816
- debt_to_equity
- 0.16072368931020556
- cash_conversion
- 0.9292491395566574
- free_cash_flow_margin
- -0.02910891002970165
- trailing_pe
- 67.6985
- forward_pe
- 18.3824
- peg_ratio
- Not supplied
- price_to_book
- 13.4817
- dividend_yield
- 0.0
Other positional research
No qualifying opportunity
No candidate at another positional horizon in the coherent source run.
- No candidate at another positional horizon in the coherent source run.
Decision provenance and limitations
- Decision ID
- decision-3d0d83529f8ba510cd5a8998b7320d905a879ba8d7e427d1694c86390c258706
- Policy
- stock-decisions-v1
- Evidence bundle hash
- 942283b7f4183ab0dd8d6055ad6942ba729411556d9feda243552bba98958119
- market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
- validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
- financial-statements: b0a5eb4b997a0ea94314bb0813c1e4ef73b7493e3aaba08f7394e680d03358c6
- daily-price: c0fbbe0cb98057ca75497c0038e4ed81e8efeab37ac0b9107b5753a7022e5ba2
- Conditional research decisions are not orders or personalized position sizes.
- Scenario payoffs are assumptions, not probabilities or expected returns.
- A stop price does not guarantee a maximum loss through a gap or illiquidity.
Download the decision evidence as JSON
Numerical report available. Evidence briefing is queued or awaiting retry.
Cached observations and evidence limits
- Price source verification: REPAIRED.
- The cached closing price on 2026-10-01 was INR 21505.00.
- The trailing 5-session price return was -1.83%.
- The trailing 20-session price return was -6.34%.
- The trailing 60-session price return was 14.06%.
- The trailing 250-session price return was 45.27%.
- Average cached traded value over twenty sessions was INR 1,069,069,405.
- The closing price was -10.38% below its highest close in the available trailing year.
- Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-23T23:41:38.244641+00:00 from EODHD.
- The cached financial metric latest annual period is 2026-03-31.
- The cached financial metric revenue growth is 0.41035321062637364.
- The cached financial metric net margin is 0.17993130350817163.
- The cached financial metric roe is 0.1941870698690816.
- The cached financial metric debt to equity is 0.16072368931020556.
- The cached financial metric cash conversion is 0.9292491395566574.
- The cached financial metric free cash flow margin is -0.02910891002970165.
- Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.